Apricus Biosciences, Inc.: Apricus Biosciences Announces National Phase Approval for Erectile Dysfunction Cream - Vitaros(R) in

   Apricus Biosciences, Inc.: Apricus Biosciences Announces National Phase        Approval for Erectile Dysfunction Cream - Vitaros(R) in Belgium  Vitaros(R) Remains on Track for Launch in 2014   SAN DIEGO, Jan. 23, 2014 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc.  ("Apricus" or the "Company") (Nasdaq:APRI) (www.apricusbio.com), today  announced that Belgium's Ministry of Social Affairs, Public Health and  Environment has granted national phase approval to Vitaros^®, indicated for  the treatment of patients with erectile dysfunction ("ED"). The Company has  now received a total of eight national phase approvals for Vitaros^®,  including Belgium, France, Germany, Ireland, Italy, the Netherlands, Sweden  and the United Kingdom ("UK") following its broad approval by European  health authorities in June 2013. Apricus has an exclusive commercialization  partnership in place with Hexal AG, an affiliate within the Sandoz Division  of the Novartis Group of Companies ("Sandoz"), for the commercialization of  Vitaros^® in several European countries, including Belgium.   "We are pleased to be working with our partner Sandoz as they make progress  towards preparing Vitaros^® for commercial launch in their licensed  territories including Belgium," said Richard Pascoe, Chief Executive Officer  of Apricus."We remain excited about the opportunity for all of our existing  partners to bring the first and only on-demand, topical erectile dysfunction  treatment to the market this year."   In June 2013, Apricus announced that its marketing application for Vitaros^®  was approved through the European Decentralized Procedure ("DCP").Under the  DCP, Apricus filed its application for marketing approval designating the  Netherlands as the Reference Member State ("RMS") on behalf of nine other  European Concerned Member States ("CMS") participating in the procedure.The  Company continues to work toward obtaining the remaining national phase  approvals in Spain and Luxembourg.    Once launched, Vitaros^® will become the first new and novel ED product in  nearly a decade, and with its unique product profile that addresses a large  number of patients who cannot or do not respond well to the existing  therapies, or who are intolerant to the systemic effects of PDE-5  inhibitors, it is well-positioned for commercial success.In Europe alone,  the existing ED products generated over $1 billion in sales in 2012.Apricus  believes that a significant portion of the market remains untreated or  under-treated, which represents a substantial commercial opportunity for  Vitaros^®.   Vitaros^® is currently partnered in key markets, including with Takeda in  the UK, Sandoz in Germany, Switzerland and certain countries in Northern  Europe, Bracco in Italy, Majorelle in France, Monaco and certain African  countries, and Abbott in Canada.The Company's existing commercialization  partners are preparing for Vitaros^® product launches in their respective  territories with product launches expected throughout 2014.    About Vitaros^®   Vitaros^® has been approved for the treatment of ED by the European health  authorities and by Health Canada. Vitaros^® is a topically-applied cream  formulation of alprostadil, a vasodilator, combined with our proprietary  permeation enhancer DDAIP.HCl, which directly increases blood flow to the  penis, causing an erection.Alprostadil is a widely accepted alternative to  the PDE-5 inhibitors for difficult to treat patients, and Vitaros^®, which  was determined to be safe and effective by the European health authorities  and previously by Health Canada, offers greater market opportunity due to  its patient-friendly form versus other alprostadil dosage forms and also  relative to oral ED products.With nearly 150 million men worldwide who  suffer from ED and an ED market size of approximately $1 billion in revenue  in Europe alone, Vitaros^® represents a major market opportunity for Apricus  and its commercial partners given its unique product profile and its  potential to treat a large underserved population.   About Apricus Biosciences, Inc.   Apricus Biosciences, Inc. (APRI) is a pharmaceutical company that develops  and markets through its licensing partners innovative treatments that have  the potential to help large patient populations across numerous,  large-market therapeutic classes including male and female sexual  health.The Company has one approved product, Vitaros^®, for the treatment  of erectile dysfunction, which is now approved in Europe and Canada and will  be commercialized by Apricus' marketing partners, which include Abbott  Laboratories Limited, Takeda Pharmaceuticals International GmbH, Hexal AG  (Sandoz), Bracco SpA and Laboratoires Majorelle.Femprox^®, the Company's  product candidate for the treatment of female sexual interest/arousal  disorder, has successfully completed a nearly 400-subject proof-of-concept  study.   For further information on Apricus, visit http://www.apricusbio.com.   Apricus' Forward-Looking Statement Safe Harbor   Statements under the Private Securities Litigation Reform Act, as amended:  with the exception of the historical information contained in this release,  the matters described herein contain forward-looking statements that involve  risks and uncertainties that may individually or mutually impact the matters  herein described for a variety of reasons that are outside the control of  the Company, including, but not limited to, its ability to further develop  its product Vitaros^® for ED, such as the room temperature version of  Vitaros^® and product candidate Femprox^® for female sexual interest/arousal  disorder among others; to have its product and product candidates receive  additional patent protection and be approved by relevant regulatory  authorities in Europe, the United States, Canada and in other countries,  such as additional national phase approvals for Vitaros^® in the remaining  CMS territories, Spain and Luxembourg; to successfully commercialize such  product and product candidates and other NexACT® product candidates and drug  delivery technology; and to achieve its other development, commercialization  and financial goals, such as successfully manufacturing and launching  Vitaros^® in partnered territories. Readers are cautioned not to place undue  reliance on these forward-looking statements as actual results could differ  materially from the forward-looking statements contained herein. Readers are  urged to read the risk factors set forth in the Company's most recent annual  report on Form 10-K, as amended, subsequent quarterly reports filed on Form  10-Q, as amended, and other filings made with the SEC. Copies of these  reports are available from the SEC's website or without charge from the  Company.  CONTACT: Apricus Investor Relations:                   David Pitts or Lourdes Catala          Argot Partners          212-600-1902          david@argotpartners.com          lourdes@argotpartners.com  ------------------------------------------------------------------------------  This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Apricus Biosciences, Inc. via Globenewswire HUG#1756761